Search Result

Results for "

protease-cleavable

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Linker (4) Antibody-Drug Conjugates (ADCs) (6) Biochemical Assay Reagents (2) Collagen (1) DNA Alkylator/Crosslinker (1) Drug-Linker Conjugates for ADC (3) Interleukin Related (1) Nectin-4 (2) Notch (1) Topoisomerase (1)
By Research Areas:	Cancer (15) Inflammation/Immunology (1)
Click Chemistry:	DBCO (1)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-114233

MC-GGFG-Exatecan Maximum Cited Publications 6 Publications Verification MC-GGFG-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-132257

Rovalpituzumab tesirine SC-002	Antibody-Drug Conjugates (ADCs) Notch	Cancer
Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .

HY-P99683

Ladiratuzumab vedotin SGN-LIV1A	Antibody-Drug Conjugates (ADCs)	Cancer
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .

HY-P3159

VPM peptide	Biochemical Assay Reagents	Others
VPM peptide is a dithiol protease-cleavable peptide cross-linker. VPM peptide can be incorporated into the backbone of the PEG-diacrylate (PEG-DA) macromer to form PEG hydrogel .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-172287

DBCO-PEG2-Val-Cit-PAB-MMAE	ADC Linker	Cancer
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

HY-156515

MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)	Drug-Linker Conjugates for ADC	Cancer
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate for ADC, formed by conjugation of 7ethanol-10NH2-11F-Camptothecin (HY-156517) with the protease-cleavable MC-GGFG linker. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is applicable for cancer research .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P991696

Lecomkafusp alfa	Interleukin Related	Inflammation/Immunology Cancer
Lecomkafusp alfa is a fusion protein that combines human IL-2 fused via a protease cleavable peptide linker to a humanized single-domain VHH fragment anti-ALB (149-263). Lecomkafusp alfa is an immunomodulator and has antineoplastic activity .

HY-P3159A

VPM peptide TFA	Biochemical Assay Reagents	Others
VPM peptide TFA is a dithiol protease-cleavable peptide cross-linker. VPM peptide TFA can be incorporated into the backbone of the PEG-diacrylate (PEG-DA) macromer to form PEG hydrogel .

HY-W800837

t-Boc-N-amido-PEG4-Val-Cit	ADC Linker	Cancer
t-Boc-N-amido-PEG4-Val-Cit is a protease-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit dipeptide. The Val-Cit dipeptide is cleavable by cell proteases and features a carboxylic acid which is free for coupling reactions with amines to form amides. The Boc can be removed under acidic conditions to reveal a free primary amine, which may be used in a variety of reactions such as coupling or reductive amination.

HY-185492

MC-cBu-Cit-seco-CBI dimer	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
MC-cBu-Cit-seco-CBI dimer (Compound 10) is a conjugate of an ADC drug toxin molecule and a linker, which consists of a DNA alkylating agent connected to a reactive maleimide via a protease-cleavable peptidomimetic linker .

HY-P992166

AB-004	ADC Antibody Collagen	Cancer
AB-004 is a humanized monoclonal antibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research .

Cat. No.	Product Name	Type

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Fluorescent Dyes
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

Enfortumab vedotin-ejfv (solution)

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv 1 Publications Verification	Fluorescent Dyes
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

Enfortumab vedotin-ejfv

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

Cat. No.	Product Name	Target	Research Area

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P3159

VPM peptide	Biochemical Assay Reagents	Others
VPM peptide is a dithiol protease-cleavable peptide cross-linker. VPM peptide can be incorporated into the backbone of the PEG-diacrylate (PEG-DA) macromer to form PEG hydrogel .

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P3159A

VPM peptide TFA	Biochemical Assay Reagents	Others
VPM peptide TFA is a dithiol protease-cleavable peptide cross-linker. VPM peptide TFA can be incorporated into the backbone of the PEG-diacrylate (PEG-DA) macromer to form PEG hydrogel .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P991696

Lecomkafusp alfa	Interleukin Related	Inflammation/Immunology Cancer
Lecomkafusp alfa is a fusion protein that combines human IL-2 fused via a protease cleavable peptide linker to a humanized single-domain VHH fragment anti-ALB (149-263). Lecomkafusp alfa is an immunomodulator and has antineoplastic activity .

HY-P992166

AB-004	ADC Antibody Collagen	Cancer
AB-004 is a humanized monoclonal antibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research .

Cat. No.	Product Name		Classification

HY-172287

DBCO-PEG2-Val-Cit-PAB-MMAE		DBCO
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.